Immunic/Nela Dornermultiple sclerosisImmunic secured US$400 million to conclude phase 3 MS program and prepare for launchA late-week surprise from Munich-based Immunic, Inc. (listed on Nasdaq as IMUX): the company has launched a follow-on private placement of up to US$400 million and expects to close the financing later … more ➔
ApprovalAmgen wins European approval to challenge argenx and UCB for autoimmune marketThe European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB. more ➔
RoyaltiesGENFIT to receive $20M milestone from Ipsen as Iqirvo tops $200M in first full yearFrench biotech GENFIT will receive a $20 million commercial milestone payment after Ipsen reported $208 million in full-year 2025 net sales of Iqirvo in primary biliary cholangitis, surpassing the $200 … more ➔
financingEurope’s life sciences investors step up as biotech financing gap widensEurope produces world-class life sciences research, yet still struggles to finance and scale it. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67 … more ➔
AIZeon invests in Chemify to cut compound synthesis time using AI and roboticsChemify has struck a deal with Zeon, securing investment from the company’s venture capital wing and signing up to make novel compounds and materials for its new partner. more ➔
SANOFISanofiFrom Darmstadt to Paris: Belén Garijo leaves Merck to lead Sanofi after CEO exitA surprise move from Darmstadt to Paris: outgoing Merck CEO Belén Garijo is set to take the helm at French pharmaceutical group Sanofi after Paul Hudson unexpectedly failed to secure a contract extension … more ➔
rare diseasesFrench biopharma duo THX Pharma and Biocodex strike rare diseases licensing deal worth up to €173MFrench biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet … more ➔
Microbioticaclinical dataMicrobiotica’s microbiome therapy showed 63% remission in ulcerative colitis phase 1b trialCambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported … more ➔
Araris Biotech AGAntibody drug conjugatesSwiss-Japanese ADC player Araris expands Chugai pact with $780m licensing agreementZurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership … more ➔
Freepik.comAntibodyThis Memo sticks: CSL bites in Switzerland for antibody collaborationThe Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration … more ➔
Immunic/Nela Dorner
SANOFI
Microbiotica
Araris Biotech AG
Freepik.com